Zcare Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 14-12-2024
- Paid Up Capital ₹ 0.10 M
as on 14-12-2024
- Company Age 10 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.90 M
as on 14-12-2024
- Revenue 52.09%
(FY 2022)
- Profit 33.09%
(FY 2022)
- Ebitda -30.71%
(FY 2022)
- Net Worth 29.07%
(FY 2022)
- Total Assets 1.99%
(FY 2022)
About Zcare Pharma
The Company is engaged in the E-Commerce Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.90 M.
Zain Hassan and Mirza Hasan serve as directors at the Company.
- CIN/LLPIN
U51900UP2013PTC061604
- Company No.
061604
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Dec 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Zcare Pharma Private Limited offer?
Zcare Pharma Private Limited offers a wide range of products and services, including Physiotherapy & Rehab Aids, Rehabilitation Equipment, Upper Body Orthotic Devices, Clavicle Brace, Lower Body Orthotic Device, Ankle Braces, Rehabilitation Belts, Back Support Belts, Knee Braces, Lumbo Sacral Belt.
Who are the key members and board of directors at Zcare Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Zain Hassan  | Director | 30-Dec-2013 | Current |
| Mirza Hasan | Director | 02-Jan-2021 | Current |
Financial Performance of Zcare Pharma.
Zcare Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 52.09% increase. The company also saw a substantial improvement in profitability, with a 33.09% increase in profit. The company's net worth Soared by an impressive increase of 29.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zcare Pharma?
In 2019, Zcare Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 16 Nov 2021 | ₹0.90 M | Open |
How Many Employees Work at Zcare Pharma?
Zcare Pharma has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zcare Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zcare Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
